Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516221 | 0.90 | KMT2A (0.73) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL95420 | 0.88 | SMN1; SMN2 (0.67) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL18826484 | 0.85 | KMT2A (0.66) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL14192610 | 0.83 | KMT2A (0.63) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5612841 | 0.83 | TDP1 (0.77) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL14384396 | 0.83 | MTNR1A (0.76) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL2844063 | 0.83 | KMT2A (0.77) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL171438 | 0.83 | HPGD (0.71) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL3547563 | 0.81 | PKM (0.62) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL11507112 | 0.81 | MAPT (0.70) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1553098-A1 | SPIROHETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | PANASONIC CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | NONO, NAA15, USO1 | KMT2A 2233/4885MEN1 4685/4885SMN1; SMN2 4304/4885 |
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | CCR1, ACKR3, CCR10 | KMT2A 2776/4885MEN1 4518/4885SMN1; SMN2 4754/4885 |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | CXCR5, CCL11, ACKR3 | KMT2A 4140/4885MEN1 4863/4885SMN1; SMN2 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.